ArticleBMC infectious diseases2025
Exploring the incidence potential of phenol-soluble modulins among methicillin-resistant Staphylococcus aureus in Lahore, Pakistan.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Drug repurposing: a dual-mechanism antibiotic combats MRSA and its high resistant phenotypes.Frontiers in cellular and infection microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMethicillin-resistant Staphylococcus aureus (MRSA) has emerged as a major clinical and epidemiological problem over the past few decades. This study aimed to investigate antibiotic resistance patterns, incidence potential of phenol-soluble modulins (PSMs) genes and explored the associations between miscellaneous clinical specimens of MRSA and the incidence of virulent PSMs genes.
methodsThis investigation employed a total of sixty MRSA strains isolated from clinical specimens such as pus aspirates, wound swabs, ear swabs, tissue swabs, blood, and urine. Antibiotic profiling was performed via Kirby-Bauer (KB) disk diffusion method. Genetic analysis was performed for detection of S. aureus-specific 16SrRNA gene, methicillin-resistant mecA and its homologue mecC gene and the virulent determinant PSMs genes psm-α, psm-β, and psm-mec along with agr operon gene via polymerase chain reaction (PCR). Pearson's Chi-square (χ
resultsMost of MRSA isolates were obtained from pus samples. The incidence of MRSA was more pronounced in males. Notably, the highest percentage of MRSA isolates was isolated from patients aged 21-40 years. Of all isolates (100%) harboured the 16SrRNA and mecA gene, whereas none of those isolates (0%) had the mecC gene. The resistance profiles of MRSA isolates obtained from various clinical specimens were not significantly different (p > 0.05). Furthermore, vancomycin and linezolid were still effective for treating MRSA infections. Those 60 strains had 56/60 (93.4%) psm-α, 54/60 (90%) psm-β, 55/60 (91.6%) psm-mec and (48/60) 80% agr genes. A strong association was detected between the psm-β gene and MRSA strains obtained from pus samples (p = 0.01), as was the case for the psm-mec gene and MRSA strains obtained from pus samples (p = 0.03).
conclusionThe well-informed decisions could be made on the prescription of the best antibiotic therapy, the implementation of efficient control measures, and the development of anti-virulence strategies to stop the dissemination of MRSA in hospitals and clinical settings. The virulence factors PSMs may be considered as potential candidates for treating virulent MRSA infections in patients through anti-virulence strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.